Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

NovaBay Pharmaceuticals (NBY) Income from Continuing Operations (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Income from Continuing Operations for 16 consecutive years, with 1256000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Income from Continuing Operations fell 18.38% to 1256000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 6665000.0, a 1283.84% decrease, with the full-year FY2024 number at 7223000.0, changed N/A from a year prior.
  • Income from Continuing Operations was 1256000.0 for Q3 2025 at NovaBay Pharmaceuticals, up from 1891000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 5532000.0 in Q4 2023 to a low of 3290000.0 in Q1 2025.
  • A 5-year average of 918842.11 and a median of 1617000.0 in 2024 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: skyrocketed 1620.25% in 2022, then tumbled 1466.67% in 2023.
  • NovaBay Pharmaceuticals' Income from Continuing Operations stood at 158000.0 in 2021, then surged by 1620.25% to 2402000.0 in 2022, then skyrocketed by 130.31% to 5532000.0 in 2023, then crashed by 104.12% to 228000.0 in 2024, then plummeted by 450.88% to 1256000.0 in 2025.
  • Per Business Quant, the three most recent readings for NBY's Income from Continuing Operations are 1256000.0 (Q3 2025), 1891000.0 (Q2 2025), and 3290000.0 (Q1 2025).